celltrion1

FDA greenlights Celltrion HIV drug manufacturing facility in South Korea

pharmafile | March 16, 2020 | News story | Manufacturing and Production, Sales and Marketing FDA, celltrion, coronavirus, pharma 

South Korean biopharma firm Celltrion has revealed that one of its key manufacturing facilities has been given the all-clear by the FDA following an on-site inspection in January.

The visit to the site in Cheongju, the largest city in the nation’s North Chungcheong Province, was for an additional inspection in order to review new technology which was omitted in the facility’s most recent Current Good Manufacturing Practice (CGMP) report, with the FDA finding no issues requiring intervention.  

 The US regulator has since postponed its overseas inspection in light of the ongoing global coronavirus pandemic.

Among the products manufactured at the facility is the drugmaker’s three-in-one oral treatment for HIV, known as CT-G07, which is currently awaiting approval from the FDA for commercialisation in the US. Celltrion is hoping for a decision as early as April this year.

Matt Fellows

Related Content

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

Nexcella has announced that the US Food and Drug Administration (FDA) has granted orphan drug …

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for …

Latest content